

Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients

Supplementary Material




Figure S1. Incidence of all-grade hypertension with VEGFR-TKIs.




Figure S2. Incidence of high-grade hypertension with VEGFR-TKIs.




Figure S3. The relative risk of all-grade hypertension with VEGFR-TKIs versus control.




Figure S4. The relative risk of high-grade hypertension with VEGFR-TKIs versus control.

Meta-analysis estimates, given named study is omitted




Figure S5. Meta-analysis of all-grade hypertensive events associated with VEGFR-TKIs versus control: 'leave-one-out' sensitivity analysis

Meta-analysis estimates, given named study is omitted




Figure S6. Meta-analysis of high-grade hypertensive events associated with VEGFR-TKIs versus control: 'leave-one-out' sensitivity analysis